there needs to be an internal priority for aml, cardio and FTO.
1. Cardio protect (pending reformulation, P2 then IND + breakthrough designation -> pathway to approval + pathway to blockbuster commercial deal)
2. EMD AML (pathway to approval 505(b)(2), subject to recruitment and SoC industry change - limited commercial deal).
3. ALKBH5 inhibitor development program, give away this IP early on discovery as part of development partnership. Upfront cash to run further preclinical and more important foot in the door for M6A RNA eraser.
4. FTO program, last on the list. Use cash from ALKBH5 discovery to prove out FTO inhibitor platform. Make deal with ALKBH5 partner for FTO once more advanced.
Team change and cardio protect will likely occur before FTO, being RAC 2.0 would see a return of DrT at that time?
there needs to be an internal priority for aml, cardio and...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |